Journal article icon

Journal article

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

Abstract:

Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Two CYP2C9 variants--*2 (Arg144Cys) and *3 (Ile359Leu)--are associated with reduced enzyme activity and impaired substrate metabolism. We identified 1,073 incident users of sulfonylureas in Tayside, Scotland, and assessed the impact of the combined CYP2C9*2 and CYP2C9*3 genotypes on early and sustained sulfonylurea response. We found that patients with two copies of a loss-of-function allele were 3.4 times (P = 0...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/clpt.2009.176

Authors


Expand authors...
Journal:
Clinical pharmacology and therapeutics
Volume:
87
Issue:
1
Pages:
52-56
Publication date:
2010-01-05
DOI:
EISSN:
1532-6535
ISSN:
0009-9236
URN:
uuid:ac629ef8-d1cf-414c-883f-e50dd5912de8
Source identifiers:
41507
Local pid:
pubs:41507

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP